<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810507</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-GDL-404</org_study_id>
    <nct_id>NCT04810507</nct_id>
  </id_info>
  <brief_title>MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus</brief_title>
  <acronym>ACACIA</acronym>
  <official_title>A Multi-center, Active Controlled, Randomized, Double-blinded, Parallel, Phase IV Study to Evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared With Sitagliptin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory study to evaluate the Effect of Improving Glycemic Variability of Anagliptin&#xD;
      Compared with Sitagliptin in Patients with Type 2 Diabetes Mellitus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is an exploratory study, and does not calculate the subject number based&#xD;
      on statistical assumptions, and enrolls 50 subjects per group and a total of 100 subjects are&#xD;
      registered to evaluate the effect of improving blood glucose variability in type 2 patients&#xD;
      with anagliptin 100 mg twice a day(BID) and sitagliptin 100 mg once a day(QD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">January 5, 2021</completion_date>
  <primary_completion_date type="Actual">September 2, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Multi-center, Active controlled, Randomized, Double-blinded, Parallel Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Improving Glycemic Variability</measure>
    <time_frame>3 days after 12 weeks treatment</time_frame>
    <description>Mean amplitude of glycemic excursion (MAGE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average nighttime (18:00~07:59) blood glucose change after 12 weeks compared to baseline</measure>
    <time_frame>after 12 weeks treatment</time_frame>
    <description>after 12 weeks compared to baseline in the test group and the control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Anagliptin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anagliptin 100 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagliptin BID Treatment</intervention_name>
    <description>Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks</description>
    <arm_group_label>Anagliptin arm</arm_group_label>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
    <other_name>Sitagliptin QD Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 DM&#xD;
&#xD;
          -  Metformin monotherapy for more than 8 weeks and metformin ≥ 1000 mg daily for more&#xD;
             than 8 weeks.&#xD;
&#xD;
          -  6.5% ≤HbA1c&lt; 8.5%&#xD;
&#xD;
          -  Agreed Therapeutic Lifestyle change during the study period&#xD;
&#xD;
          -  Obtained Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus,&#xD;
&#xD;
          -  History of intestinal obstruction&#xD;
&#xD;
          -  NYHA class III to IV congestive heart failure,&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 X upper limit&#xD;
             of normal (ULN) or Total bilirubin &gt; 3 X ULN&#xD;
&#xD;
          -  Creatinine clearance (CrCl)* &lt; 50 mL/min&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) ≥ 1.5 X ULN&#xD;
&#xD;
          -  Allergic history for Anagliptin 또는 sitagliptin&#xD;
&#xD;
          -  Being pregnant or nursing or suspected of being pregnant, or&#xD;
&#xD;
          -  History of participation in other clinical studies in the preceding 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaewan Park</last_name>
    <role>Study Director</role>
    <affiliation>JWPharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Anagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

